Haleon to take full ownership of Chinese joint venture
announced on Tuesday that it has agreed to acquire the remaining 12% stake in its Chinese over-the-counter joint venture, Tianjin TSKF Pharmaceutical, for CNY 1.623bn (around £200m), bringing its total ownership to 100%.
The FTSE 100 consumer products giant said the deal followed its acquisition of a 33% stake in TSKF in December, and would result in the business becoming a wholly-owned subsidiary.
It said the transaction would be funded through a mix of existing cash and new renminbi-denominated debt from third-party sources.
Completion was expected within the next three months, subject to customary conditions including shareholder approval from Haleon's partner Tianjin Pharmaceutical Da Ren Tang Group, and necessary regulatory clearances.
At 1135 BST, shares in Haleon were up 0.04% at 379.14p.
Reporting by Josh White for Sharecast.com.
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.